Difference between revisions of "Senile dementia"

From Aging Chart
Jump to: navigation, search
(Autoloading by CXLParser)
(Autoloading by CXLParser)
 
Line 260: Line 260:
 
(.//.)<html><!--Pop-up for: Senile plaques !Pop-up-->
 
(.//.)<html><!--Pop-up for: Senile plaques !Pop-up-->
 
<div class="1J13DNQZ3-WQRX7P-2Y3" style="display:none;">
 
<div class="1J13DNQZ3-WQRX7P-2Y3" style="display:none;">
 +
  
  
Line 271: Line 272:
 
</div>(...)<!--Pop-up for: Infections  !Pop-up-->
 
</div>(...)<!--Pop-up for: Infections  !Pop-up-->
 
<div class="1J139D7TL-27QTCB7-QH" style="display:none;">
 
<div class="1J139D7TL-27QTCB7-QH" style="display:none;">
 +
  
  
Line 282: Line 284:
 
</div>(...)<!--Pop-up for: Trophic disturbances !Pop-up-->
 
</div>(...)<!--Pop-up for: Trophic disturbances !Pop-up-->
 
<div class="1J13CXN2F-1WG94Q6-1Y3" style="display:none;">
 
<div class="1J13CXN2F-1WG94Q6-1Y3" style="display:none;">
 +
  
  
Line 293: Line 296:
 
</div>(...)<!--Pop-up for: Lipofuscin !Pop-up-->
 
</div>(...)<!--Pop-up for: Lipofuscin !Pop-up-->
 
<div class="1J139BS6X-22MJ3GP-P7" style="display:none;">
 
<div class="1J139BS6X-22MJ3GP-P7" style="display:none;">
 +
  
  
Line 304: Line 308:
 
</div>(...)<!--Pop-up for: Proteins glycation !Pop-up-->
 
</div>(...)<!--Pop-up for: Proteins glycation !Pop-up-->
 
<div class="1J139KLKM-1LCXD42-V0" style="display:none;">
 
<div class="1J139KLKM-1LCXD42-V0" style="display:none;">
 +
  
  
Line 315: Line 320:
 
</div>(...)<!--Pop-up for: Inflammation !Pop-up-->
 
</div>(...)<!--Pop-up for: Inflammation !Pop-up-->
 
<div class="1J139B985-1ZQTZHN-NJ" style="display:none;">
 
<div class="1J139B985-1ZQTZHN-NJ" style="display:none;">
 +
  
  
Line 326: Line 332:
 
</div>(...)<!--Pop-up for: Synapses degeneration !Pop-up-->
 
</div>(...)<!--Pop-up for: Synapses degeneration !Pop-up-->
 
<div class="1J1396FH6-21PP2DZ-JL" style="display:none;">
 
<div class="1J1396FH6-21PP2DZ-JL" style="display:none;">
 +
  
  
Line 337: Line 344:
 
</div>(...)<!--Pop-up for: Separate neuron groups  (dopaminergic, cholinergic) !Pop-up-->
 
</div>(...)<!--Pop-up for: Separate neuron groups  (dopaminergic, cholinergic) !Pop-up-->
 
<div class="1N9KPYC9B-4K0LLK-1Q6P" style="display:none;">
 
<div class="1N9KPYC9B-4K0LLK-1Q6P" style="display:none;">
 +
  
  
Line 348: Line 356:
 
</div>(...)<!--Pop-up for: Oxidative stress !Pop-up-->
 
</div>(...)<!--Pop-up for: Oxidative stress !Pop-up-->
 
<div class="1J139HFXV-1YVJ5KD-S8" style="display:none;">
 
<div class="1J139HFXV-1YVJ5KD-S8" style="display:none;">
 +
  
  
Line 359: Line 368:
 
</div>(...)<!--Pop-up for: Phenolic  Amines (NTox) !Pop-up-->
 
</div>(...)<!--Pop-up for: Phenolic  Amines (NTox) !Pop-up-->
 
<div class="1J13F7FY6-1B2SLXD-3JR" style="display:none;">
 
<div class="1J13F7FY6-1B2SLXD-3JR" style="display:none;">
 +
  
  
Line 370: Line 380:
 
</div>(...)<!--Pop-up for: Copper ions !Pop-up-->
 
</div>(...)<!--Pop-up for: Copper ions !Pop-up-->
 
<div class="1J13D7HX2-23RYYYV-2BF" style="display:none;">
 
<div class="1J13D7HX2-23RYYYV-2BF" style="display:none;">
 +
  
  
Line 381: Line 392:
 
</div>(...)<!--Pop-up for: Mitochondrial  Dysfunction !Pop-up-->
 
</div>(...)<!--Pop-up for: Mitochondrial  Dysfunction !Pop-up-->
 
<div class="1J139F328-1LRS67J-R7" style="display:none;">
 
<div class="1J139F328-1LRS67J-R7" style="display:none;">
 +
  
  
Line 392: Line 404:
 
</div>(...)<!--Pop-up for: Platelet  Activating factor !Pop-up-->
 
</div>(...)<!--Pop-up for: Platelet  Activating factor !Pop-up-->
 
<div class="1J13FK5JT-1GBXCWM-442" style="display:none;">
 
<div class="1J13FK5JT-1GBXCWM-442" style="display:none;">
 +
  
  
Line 403: Line 416:
 
</div>(...)<!--Pop-up for: Senile dementia !Pop-up-->
 
</div>(...)<!--Pop-up for: Senile dementia !Pop-up-->
 
<div class="1J13BFW49-9W6HPG-143" style="display:none;">
 
<div class="1J13BFW49-9W6HPG-143" style="display:none;">
 +
  
  
Line 414: Line 428:
 
</div>(...)<!--Pop-up for: Myelin damage !Pop-up-->
 
</div>(...)<!--Pop-up for: Myelin damage !Pop-up-->
 
<div class="1J13CSKJN-DSN3J7-1SN" style="display:none;">
 
<div class="1J13CSKJN-DSN3J7-1SN" style="display:none;">
 +
  
  
Line 425: Line 440:
 
</div>(...)<!--Pop-up for: Quinolinic  Acid !Pop-up-->
 
</div>(...)<!--Pop-up for: Quinolinic  Acid !Pop-up-->
 
<div class="1J13DFJT7-2B8CJ4G-2LL" style="display:none;">
 
<div class="1J13DFJT7-2B8CJ4G-2LL" style="display:none;">
 +
  
  
Line 436: Line 452:
 
</div>(...)<!--Pop-up for: Microglia changes !Pop-up-->
 
</div>(...)<!--Pop-up for: Microglia changes !Pop-up-->
 
<div class="1J13D1S6Q-1MGM8YQ-219" style="display:none;">
 
<div class="1J13D1S6Q-1MGM8YQ-219" style="display:none;">
 +
  
  
Line 447: Line 464:
 
</div>(...)<!--Pop-up for: Cerebral atherosclerosis !Pop-up-->
 
</div>(...)<!--Pop-up for: Cerebral atherosclerosis !Pop-up-->
 
<div class="1J13BLR95-19DY8FH-19Q" style="display:none;">
 
<div class="1J13BLR95-19DY8FH-19Q" style="display:none;">
 +
  
  
Line 458: Line 476:
 
</div>(...)<!--Pop-up for: Disturbances in neocortex, hippocampus, hypothalamus, substantia nigra !Pop-up-->
 
</div>(...)<!--Pop-up for: Disturbances in neocortex, hippocampus, hypothalamus, substantia nigra !Pop-up-->
 
<div class="1J13FWZB8-1GJ6DPR-4KL" style="display:none;">
 
<div class="1J13FWZB8-1GJ6DPR-4KL" style="display:none;">
 +
  
  
Line 469: Line 488:
 
</div>(...)<!--Pop-up for: Injuries  !Pop-up-->
 
</div>(...)<!--Pop-up for: Injuries  !Pop-up-->
 
<div class="1J1399ZLS-1KCBBCJ-N2" style="display:none;">
 
<div class="1J1399ZLS-1KCBBCJ-N2" style="display:none;">
 +
  
  
Line 480: Line 500:
 
</div>(...)<!--Pop-up for: Hypertension  !Pop-up-->
 
</div>(...)<!--Pop-up for: Hypertension  !Pop-up-->
 
<div class="1J13CRWTB-B7X8M9-1RP" style="display:none;">
 
<div class="1J13CRWTB-B7X8M9-1RP" style="display:none;">
 +
  
  
Line 491: Line 512:
 
</div>(...)<!--Pop-up for: Dopamine  Oxidation !Pop-up-->
 
</div>(...)<!--Pop-up for: Dopamine  Oxidation !Pop-up-->
 
<div class="1J139QCJ3-QG8QGF-VZ" style="display:none;">
 
<div class="1J139QCJ3-QG8QGF-VZ" style="display:none;">
 +
  
  
Line 502: Line 524:
 
</div>(...)<!--Pop-up for: Ischemia  !Pop-up-->
 
</div>(...)<!--Pop-up for: Ischemia  !Pop-up-->
 
<div class="1J1399SKF-2421FX1-MQ" style="display:none;">
 
<div class="1J1399SKF-2421FX1-MQ" style="display:none;">
 +
  
  
Line 513: Line 536:
 
</div>(...)<!--Pop-up for: Glutamate !Pop-up-->
 
</div>(...)<!--Pop-up for: Glutamate !Pop-up-->
 
<div class="1J13D83HL-19F51S7-2CD" style="display:none;">
 
<div class="1J13D83HL-19F51S7-2CD" style="display:none;">
 +
  
  
Line 524: Line 548:
 
</div>(...)<!--Pop-up for: Amyloid  !Pop-up-->
 
</div>(...)<!--Pop-up for: Amyloid  !Pop-up-->
 
<div class="1J139BZGQ-2CD52M2-PQ" style="display:none;">
 
<div class="1J139BZGQ-2CD52M2-PQ" style="display:none;">
 +
  
  
Line 535: Line 560:
 
</div>(...)<!--Pop-up for: Neurotoxic effects !Pop-up-->
 
</div>(...)<!--Pop-up for: Neurotoxic effects !Pop-up-->
 
<div class="1J13D6FDC-1KHG0XN-28Q" style="display:none;">
 
<div class="1J13D6FDC-1KHG0XN-28Q" style="display:none;">
 +
  
  
Line 546: Line 572:
 
</div>(...)<!--Pop-up for: Axons damage !Pop-up-->
 
</div>(...)<!--Pop-up for: Axons damage !Pop-up-->
 
<div class="1N9KNVRDW-5GSLT2-1PW5" style="display:none;">
 
<div class="1N9KNVRDW-5GSLT2-1PW5" style="display:none;">
 +
  
  

Latest revision as of 09:26, 2 August 2015

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Senile dementia

Senile dementia (SD) is a chronic and progressive disease that occurs in the elderly. Organic brain damage manifests as impaired mental function; behavioral disorders; and personality changes in cognition, memory, judgment, speech, emotion and thinking. SD encompasses a group of clinical syndromes and functional declines in daily life and social activities, which last for 4–6 months or more, and are mostly irreversible. Late-life dementia, in contrast to early-onset AD, can reflect damage to the brain by a wide range of vascular and nonvascular factors. to varying degrees, obesity, hypertension, diabetes, atrial fibrillation, high cholesterol, congestive heart failure, inflammatory conditions (such as lupus), obstructive sleep apnea (OSA), education, exercise, chronic stress, and depression can all alter brain architecture transiently or permanently at the cellular or macroscopic level.

Alzheimer’s disease (AD) is a progressive type of senile dementia affecting a large number of the elderly population. The pathological hallmarks of the disease are selective neuronal loss, numerous extracellular deposits termed senile plaques, and intraneuronal neurofibrillary tangles (NFTs) in the patient’s brain. The major component of senile plaques is a 39 to 43 amino acid peptide termed b-amyloid protein (AbP), which is a proteolytic product of a large precursor glycoprotein, the amyloid precursor protein (APP). Intracerebral application of AbP caused a decrease of choline acetyl transferase activity, impairment of long term potentiation, and the memory disorder. Furthermore, conformational changes of AbP have been linked to its neurotoxicity. AbP is a hydrophobic peptide and has the intrinsic property of forming aggregates with b-pleated sheet structures. A growing number of reports suggest that b-pleated sheet-AbP aggregates are neurotoxic. The neurotoxicity of AbP and its association with conformational changes of the peptide have been suggested to imply the etiological significance in the pathogenesis of AD.

Microglia, the resident innate immune cells in the brain, have been implicated as active contributors to neuron damage in neurodegenerative diseases, in which the overactivation and dysregulation of microglia might result in disastrous and progressive neurotoxic consequences. Pattern recognition receptors (PRRs) are tools used by microglia to identify neurotoxic stimuli and that stimulation of NADPH oxidase activity is the predominant mechanism through which microglia produce neurotoxic reactive oxygen species (ROS). Normal aging in the human brain is accompanied by increasing numbers of activated, interleukin 1β (IL-1β)-expressing microglia90 and enlarged phagocytic microglial subtypes. Several reports propose that the age-associated transformation of microglia is a reflection of a chronic, lifelong accumulation of minor insults leading to increased risk of neurodegenerative disease, such as Alzheimer’s disease.